Prof. Kannan Vaidyanathan

Professor & Head, Dept of Biochemistry, Believers Church Medical College Hospital (BCMCH), Tiruvalla since February 2022; Fellow, Royal College of Physicians (Edinburgh) (UK) [FRCP (Edin.) (UK)]; President (Association of Clinical Biochemists of India (ACBI). He was Professor, Department of Biochemistry & Head, Molecular Biology, Amrita Institute of Research Center (AIMS), Kochi (2019-2022), Professor & Head, Dept of Biochemistry & Deputy Medical Superintendent, Pushpagiri Institute of Medical Science, Tiruvalla (2013-2019); Head, Metabolic Disorders Laboratory, AIMS & Deputy Technical Manager of Amrita Laboratory Services (2006-2013). He has also worked at Govt. Medical College, Kottayam and Kochi.

APFCB (Asia Pacific Federation of Clinical Biochemists) International Silver Jubilee scholarship, November 2007.
“KP Sinha – PS Krishnan Award” - Best Paper award for best original research paper published in Indian Journal of Clinical Biochemistry published for the year 2011.
ICMR Travel Fellowship to attend EuromedLab Barcelona 2019, 23rd IFCC-EFLM Conference on Clinical Chemistry, Barcelona, Spain on 19th – 23rd May 2019.
“Trialect” Priority Fellowship – Short-term Fellowship at Torino University, Italy (October 2023) (Under Dr. Chiara Riganti).
Co-Editor-In-Chief, eJIFCC & EC Member, CPD (IFCC).
Associate Editor, Indian Journal of Clinical Biochemistry (IJCB) Indexed in PubMed Central and published by Springer.
Associate Editor, Clinical Biochemists Reviews (CBR) Published by APFCB (Asia Pacific Federation of Clinical Biochemists).
Consultant, IFCC-ISNS TF-NBS Task Force.
Member, PG Board of Studies, Kerala University of Health Sciences (KUHS), Kerala.

Dr Jairam Rawtani
Senior Professor and Ex HOD
Department of Biochemistry
Government Medical College Kota Rajasthan

Published 20 Papers and One Book Associate Editor IJCB Ex Vice President ACBI State Representative Rajasthan Joint Secretary Rajasthan ACBI Organized CME and state conferences.

Prof.ANISSA ATIF MIRZA
Head of Biochemistry AIIMS Rishikesh

• Total 27 Years of Teaching and Research Experience in field of Medical Biochemistry
• Established and Developed Academics, Diagnostics and Research of Biochemistry Department at AIIMS Rishikesh since 2012
• Associate Dean Exam, Chairperson of Ph D Committee, Member of PG Thesis Review Committee of Research
• Area of Research Interest: Cancer Biochemistry, Naturobiochemistry and Preventive Biochemistry through behavior
• Working on Collaborative Intramural and Extramural Research projects
• Approximate 90 Research Publications in Research Journals
• Awarded as best Teacher of Biochemistry in 2021 during Teachers Day Celebration of AIIMS Rishikesh
• Received Best Researcher award in 2022 during Research Day Celebration at AIIMS Rishikesh
• Worked to initiate DM course - Metabolic Medicine in Biochemistry

Prof.Sheikh Mumtaz Hadi
I possess more than 40 years experience of teaching and research in Molecular Biology. A number of these years were spent in laboratories in the USA, Switzerland and the UK. In Switzerland I had the occasion to work in the laboratory of Nobel Laureate Prof. W. Arber (discoverer of restriction enzymes) at the University of Basel.

My entire research career has been in the area of structure and function of nucleic acids. As evidenced by my publications I have contributed significantly in the areas of DNA repair enzymology, DNA restriction and modification enzymes and recombinant DNA techniques. For the past several years I have been interested in DNA damage mechanisms involved in chemically induced carcinogenesis and chemopreventive mechanisms.

Specifically we have been studying the mechanism of action of certain dietary and naturally occuring polyphenolics and antioxidants. Our studies have shown that several of the known biological antioxidants are themselves capable of DNA damage under appropriate conditions. Further, it is now recognised that considerable DNA damage may be caused by endogenous metabolites formed during the body’s normal metabolic processes. Such damage is considered to possibly define the base line of the induction of human cancer. We have shown that metabolites such as L-DOPA, bilirubin and uric acid are capable of oxidative DNA damage giving rise to modified bases. Studies with plant derived polyphenolic compounds such as tannins and stilbenes have indicated that the prooxidant action of these compounds is likely to be the mechanism involved in apoptosis induction observed in various cancer cell lines. During the course of such studies a number of papers have been published in journals of repute and several students have obtained Ph.D. degree.

Citation Award: I was awarded as the top ten cited author by Elsevier for our paper entitled “Oxidative breakage of cellular DNA by plant polyphenols: A putative mechanism for anticancer properties” published in Seminars in Cancer Biology 17 (2007) 370–376

Prof.Anil Chuturgoon
Dr Anil Chuturgoon is a Medical Biochemist and has a PhD in toxicology (food mycotoxins) and epigenetics. He is Professor and Head of Medical Biochemistry and is currently the Dean of Research in the College of Health Sciences (University of KwaZulu-Natal, Durban, South Africa). He is a B rated medical scientist by the National Research Foundation; has published over 200 research papers, 12 chapters in books, edited two books and many conference proceedings. He has an H-index of 34. He is actively researching epigenetic phenomena in toxicology and its implications in human diseases. He is an expert on mycotoxins and their biological toxicity in humans. He pioneered research on fusariotoxins and epigenetics and their implication in disease. His contribution to Toxicology has been recognised by CTD curator (supported by the National Institute of Environmental Health Sciences, USA) where 8 of his manuscripts are included in this database. This database provides manually curated information about chemical–gene/protein interactions, chemical–disease and gene–disease relationships. He has successfully supervised and graduated over 150 Master's and 50 PhD students. He serves as editor on several prestigious journals; is a member of the South African Society of Biochemistry and Molecular Biology and executive member of South African Society of Clinical Biochemists. He is an avid mountain biker.

Prof.Bernard GOUGET

Dr Bernard GOUGET
President, National Committee for the selection of Reference Laboratories, DGS-PP1-Ministry of Health and Prevention
Past-President-Healthcare Division Executive Committee, Comité Français d’accréditation (Cofrac)
Secretary, IFCC Emerging technologies Division Chair, IFCC-TF on History
b.gouget@icloud.com

Dr. Bernard Gouget, Ph.D, MSc, LL.D. is past President-Healthcare Division Executive Committee, Comité Français d’accréditation (Cofrac) and President, National Committee for the selection of Reference Laboratories, Ministry of Health. He was associate Professor at the Faculty of Medecine Necker-Children Hospital Centre University Paris and Counsellor for public health at the Fédération Hospitalière de France (FHF) until 2019. Academically, Dr. Gouget has also received a Master in Health economy and a doctorate in Economy and Law.

His professional and research interests include organ physiology in intensive care and the adaptation of health care services to required standards of patient care, disruptive technologies, biomedicine and ethics. He started with IFCC in the beginning of the 90’.Over the past 30 years, he has participated in a number of medical committees and panels at national and international levels as SFBC-EFCC/EFLM representative ( 2005-2016); Chair-EFCC WG on Communication (2010-2011); LABAC-EFLM representative since 2018. He was IFCC-CPD chair (1998-2003), Member and Treasurer at the IFCC-EB (2009-2014), Chair of the IFCC Nomination committee (2015-2017). As current Chair of the TF on IFCC History, he is writing the IFCC's anniversary book. He was President of EuroMedLab Paris 2015 and President of the IFCC General Conference Madrid 2016.

As President of IFCC C-MHBLM (2018-2023) and currently Secretary of the IFCC Emerging Technologies Division since 2024, he works on AI and quantum analysis, smart technologies and quality management that are transforming the traditional healthcare system in a global way and making laboratory medicine more practical, efficient and personalized for sustainable development in the digital decade of the 2020s and beyond .

Prof.Gruson

Professor Damien Gruson serves as the Head of the Department of Laboratory Medicine at the Cliniques Universitaires Saint Luc in Brussels. Additionally, he holds teaching position and a membership in the research unit focusing on Endocrinology, Diabetes, and Nutrition at UCLouvain .

He holds the esteemed position of Chair within the division on Emerging Technology at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Furthermore, Professor Gruson serves as a board member for the Royal Belgian Society of Laboratory Medicine and of the Belgian Thyroid Club. Prof. Gruson holds fellowships in the European Society of Cardiology, the Heart Failure Association, and the American Association of Clinical Chemistry Academy. Notably, Professor Gruson is the President of the upcoming Euromedlab Congress scheduled to be held in Brussels in 2025

Prof.Hari K Koul

Hari K. Koul, M.Sc., Ph.D. FACN, FASN Louisiana University Health Sciences Center- New Orleans-LA
Dr. Hari K. Koul is Professor in the Departments Interdisciplinary Oncology, Biochemistry and Molecular biology and Urology. He serves as Associate Director for the LSU-LCMC Cancer Center and Head of the GU Oncology Research Program at LSUHSC. He is recognized as one of the leading translational researchers in urologic diseases. He is listed among the top 2% of scientists in the world for 2024 (https://www.adscientificindex.com/scientist/hari-koul/1355019 ). His current research interests are focused on GU oncology with special emphasis on understanding the pathophysiology of prostate cancer. Over the past three decades, Dr. Koul has greatly contributed to our understanding of molecular mechanisms, in oxalate nephron-toxicity and prostate cancer. Dr. Koul’s research is focused on understanding the mechanisms tumor progression and emergence of therapeutic resistance, with special focus on epigenetic mechanisms.

Dr. Koul earned B.Sc. (Biology and Chemistry) 1984 and M.Sc. (Biochemistry) 1986 from Kashmir University-Srinagar, India, and Ph.D. (Biochemistry) 1990 from PGI, Chandigarh, India. Dr. Koul worked as a postdoctoral fellow (1991-1995) and Instructor (1996) at the UMASS Medical School, Worcester, MA. Dr. Koul received his first independent NIH RO1 in 1996 and relocated as Sr. Staff Scientist to Henry Ford Health Sciences Center, Detroit MI. In 2003 Dr. Koul was recruited as Professor and founding Director of Urology Research at the University of Colorado Denver, School of Medicine. In 2013, Dr. Koul was recruited to LSUHSC-S as Professor with tenure and Carroll W. Feist Endowed Chair in Cancer. He also served as Chairman of the Department of Biochemistry and Molecular Biology, School of Medicine and Associate Director for Basic and Translational Research of the Feist Weiller Cancer Center at LSUHSC-Shreveport. Dr. Koul was recruited to LSUHSC-New Orleans on 02/2020.

Dr. Koul is a tireless advocate for scientific research enterprise and is a thought leader. In recognition for his scientific contributions, tireless service and research leadership Dr. Koul has been elected, President of the Society of Basic Urology Research (Home (sbur.org) ) USA (2016-2017), President of the Research on Calculous Kinetics Society (ROCK - Welcome (rocksociety.org) ) USA (2005-2006), Fellow of the American Society of Nephrology (2010), and A Fellow of the American College of Nutrition (2004) and Co-Chair of the American Urological Association Research Grants Committee (2014-2015). He served as charter member of the American Urological Association Research Council (2007-2013; 2016-2018) and Member-at-Large/ Board of Directors of the Society of Basic Urological Research. He is recipient of Outstanding Achievement Award of the Society of American Asian Scientists in Cancer Research (2009). Charter Member of the NIH Study Section on the Urologic Kidney and Genitourinary Development (2003-2007) and US Veterans Administration Merit Review Subcommittee for Oncology (2004-2009). He also served as a member of the US Veterans Administration Merit Review Subcommittee for Surgery (2004-2008). He is frequently called to serve as a Chair/member on several NIH and DOD Panels for his expertise and leadership skills.

Prof.Khosrow Adeli

Prof. Adeli is a distinguished clinical biochemist with over 36 years of experience in clinical chemistry, education, and research. He has held numerous leadership roles in clinical biochemistry and laboratory medicine, contributing significantly to research in metabolic health, pediatric laboratory medicine, and genetic-metabolic diseases. Prof. Adeli has authored over 700 publications and abstracts and received numerous national and international awards for his research excellence, including the 2019 ADLM Outstanding Research Award and several others from the Canadian Society of Clinical Chemistry.

Elected as president of the International Federation of Clinical Chemistry & Laboratory Medicine (IFCC) in 2019, he served a three-year term and is currently on the IFCC Executive Board as past president. His research, particularly through the CALIPER studies (www.caliperproject.ca), has been highly influential both in Canada and internationally. Prof. Adeli’s contributions are evident in his extensive list of publications, with 234 peer-reviewed articles and a significant citation impact (Google Scholar: h-index of 54, i10-index of 184, and over 14,000 citations). Additionally, he is a Senior Scientist at the SickKids Research Institute, where his lipid/lipoprotein research has garnered further recognition, including the CSATVB Scientific Excellence Award and multiple Merck Senior Investigator Awards. Prof. Adeli’s work has greatly impacted clinical chemistry through his innovative research, leadership, and dedication to training future clinical chemists.

Dr. Namita Parikshit Mahalle

1) Presently working as Consultant Biochemist in Pathology Department in Deenanath Mangeshkar Hospital & Research Centre, Pune since last 17 years.

2) Previously worked with Research & Development division of Lupin Limited Pharmaceutical Company and also had worked with Poona hospital and Research Center, Pune as Medical Biochemist.

3) Awards: Dr. C. Sita Devi Award Young scientist award (twice), IFCC Task Force Young scientist award, The Global Health Travel Award funded by the Bill & Melinda Gates Foundation to present paper in conferences in China and Brazil, IFCC Roche Travel Scholarship for presenting paper in conferences in Bali, Indonesia and Nutrition Society Travel Fellowship Award to present paper in conference in Ghana, Africa.

4) Several publications in national and international journals.

5) Actively involved in research activities funded by Department of Biotechnology & foreign collaborators Aarhus University & Hospital, Denmark, along with in-house research.

Dr.Neeraj Sharma

Dr. Neeraj Sharma is an Assistant Professor in the Department of Genetic Medicine. He studies molecular genetics of cystic fibrosis (CF) disease. Neeraj received his undergraduate and postgraduate degrees in DVM followed by PhD in genetics of cystic fibrosis from Postgraduate Institute of Medical Education and Research, Chandigarh, India. He completed postdoctoral fellowship under the mentorship of Prof. Garry Cutting in the Department of Genetic Medicine at Johns Hopkins University.

Dr. Uma Kanga

Dr. Uma Kanga is an Additional Professor at the Department of Transplant Immunology and Immunogenetics at the All India Institute of Medical Sciences (AIIMS), New Delhi. She received her doctoral degree from AIIMS and further training at several prestigious institutions including Central Laboratory Blood Bank, Amsterdam; Tokai University, Japan; Children’s Hospital, Oakland, USA; Royal Free Hospital, London, UK; and Necker Hospital, Paris.

**Awards:** Dr. Kanga has been honored with fellowships from the Commonwealth Scholarship Commission (UK), the Japanese Society for Promotion of Science, and the European Board of Surgery, which conferred upon her the title of Fellow of the Board of Surgery in Transplantation Immunology. Her research work has been recognized by the European Federation of Immunogenetics (EFI) and The Transplantation Society (as Mentor-Mentee award).

**Research Interests:** Dr. Kanga's research focuses on the genomic diversity of HLA in the Indian population, molecular basis of disease susceptibility, and biomarkers for predicting transplant outcomes. Her research has received funding from both national and international agencies, and she has 82 publications to her credit. She also teaches medical students (UG & PG) and mentors PhD students.

**Clinical Services:** As the faculty in-charge of the Clinical Immunogenetics Laboratory, Dr. Kanga manages transplant immunology services for both stem cell and renal transplant programs at AIIMS. She has trained several clinicians and laboratory scientists and coordinates the National Quality Assurance Program for molecular-based HLA typing, involving 35 Indian centers.

**Role in National/International Scientific Bodies:** Dr. Kanga is the founder secretary of the Indian Society for Histocompatibility and Immunogenetics (ISHI), a member of the International HLA and Immunogenetics Workshop Council (IHIWS), the General Assembly of the International Union of Immunological Societies (IUIS) (2022-2025), and the Gender Equity Committee of IUIS (2024-2027). She has also served as Chair of the International Committee of the American Society for Histocompatibility and Immunogenetics (ASHI) (2022-2023), Councilor of the Asia Pacific Histocompatibility and Immunogenetics Association (APHIA), and Treasurer of the Indian Immunology Society.

Prof.Pamela Christudoss

Dr. Pamela , Professor and Head of Clinical Biochemistry, CMC, Vellore, has 33 years of experience in the Clin Bio lab, CMC with technical expertise in handling automated, semiautomated analysers for Chemistry and Immunoassays, RIA, ELISA’s, ICP- MS for heavy metals, Atomic absorption and special manual assays for clinically related laboratory tests. She is actively involved in trouble shooting assays, instruments and interpretation of results. Her area of specialization and interest are Protein Electrophoresis for Myeloma work up, Endocrinology, Laboratory Quality management and competency training for staff. She is actively involved in teaching students of various courses both undergraduate and postgraduate. Her PhD research topic was on ‘Tissue trace metal Zinc and colon cancer’ . She has published many papers in both national and International journals and is involved in various Research projects within the institution and multicentric international projects.

She is the Quality manager of the dept and for the EQAS programme and is involved in documents preparation for NABL accreditations. She is involved with the CMC EQAS programme since 14 years .More than 14,000 labs in India and other neighboring countries participate in this Quality programme and is the first in India and the largest EQAS programme in Asia. Her desire to see an improvement in the performance of Lab participants led her to make many changes in the programe to improve its quality. She has been an invited speaker , resource person for various scientific programmes and has conducted many workshops on “Understanding Principles and Practices of QC’ , and ‘Good clinical laboratory practice’ in various states in India.

Dr. Pamela was sent for a ‘Faculty Research Fellowship’ at Kansas University medical centre , USA in 2010, and for ‘Senior Training Fellowship’ on Quality Control at UKNEQAS Birmingham and Guildford, UK in 2018. She is the member of the Advisory committee of the M(EL) T laboratories – Medical –Entry level testing labs with NABL .

Prof.Pavai Sthaneshwar

Dr. pavai Sthaneshwar, graduated from Kilpauk Medical College, Chennai and subsequently did her post graduation from Madras Medical College. Obtained her degree in Medical Education also. She is currently holding the post of Associate Professor in the Department of Pathology. She is the academic person in-charge of Chemical Pathology for the Division of Laboratory Medicine. Her keen interests are improving the laboratory services. She is Vice Chair for MACB CKD task Force, Chair for standardisation of macroprolactin screening and reporting, and a member of national Method verification writing group. In the past she held a post in APFCB CKD Task Force.

Dr.Pradeep Dudeja

Dr. Dudeja’s group has been involved in elucidating ion transport mechanisms in the human intestine for a better understanding of mechanisms underlying pathophysiology of diarrhea and to develop better therapeutic modalities. His group has made significant contributions to the understanding of the role of chloride transporter SLC26A3 or DRA (Down Regulated in Adenoma, the congenital chloride diarrhea gene). He has also established that a down regulation in expression of this chloride transporter in IBD patients, animal models of IBD and in response to infection by food-borne pathogens is one of the key mechanisms underlying pathophysiology of diarrhea associated with IBD and infections by food borne pathogens. His studies have now established that SLC26A3 should be a novel therapeutic target for diarrheal diseases. He has also recently identified several proabsorptive molecules which upregulate intestinal chloride absorption by upregulating its expression or function including lysophosphatidic acid, neuropeptide Y, bioactive factors secreted by probiotics. In addition, his group has done pioneering work in understanding the mechanisms of absorption of colonic short chain fatty acids (SCFAs) produced by bacterial fermentation of undigested fiber in the large intestine. He has shown that SCFA absorption via a monocarboxylate transporter-1 involves a novel nutrient sensing mechanism. He has extensively published his work in respected journals (~ 260 publications to date). He serves as an academic editor for many journals including PLOS1, Pathophysiology and Comprehensive Physiology. He was recently awarded one of the most prestigious “University Scholar” award by University of Illinois at Chicago for 2011. In 2018, he was honored with “Takeda Distinguished Scientist Award” of Amer. Physiol. Soc, and in 2024 he was honored by the research mentor of the year award by intestinal disorders section of American Gastroenterology Association.

Prof.Qing H Meng

Dr. Meng is Professor and the Section Chief of Clinical Chemistry in the Department of Laboratory Medicine at The University of Texas MD Anderson Cancer Center. He also serves as the Director of Clinical Chemistry Postdoctoral Training Program at MD Anderson Cancer Center.

Dr. Meng's research interests focus tumor biology, biomarkers, liquid biopsy, and cancer diagnostics. He has received numerous research grants, including NIH R01 and R21. Dr. Meng has published over 150 peer-reviewed papers. He has given presentations at prestigious national and international conferences. Dr. Meng holds editorial roles as the Associate Editor of Clinical Biochemistry and the Section Editor of Clinical Pathology for Annals of Medicine, and serves on the Editorial Board of CCLM, CCA, CRCLS, and JALM, and among others.

Dr. Meng has played integral roles in various national and international professional societies and organizations including Canadian Society of Clinical Chemists (CSCC), Association for Diagnostics and Laboratory Medicine (ADLM), and IFCC. Currently he is the ADLM (formerly AACC) Academy President, Chair of ADLM Global Lab Quality Initiative (GLQI) Asia Pacific Working Group (APWG), Co-Chair of IFCC Task Force on Global Lab Quality (TF-GLQ), CLSI Expert Panel on Clinical Chemistry and Toxicology, FDA Medical Devices Advisory Committee, Clinical Chemistry and Clinical Toxicology Devices Panel, and WHO IVD advisor.

Dr. Meng has received numerous awards from prominent professional societies, including the AACC, AACC Academy, CSCC, and CACB. Notable accolades include the CSCC Research Excellence Award, CACB Outstanding Service to the Profession of Clinical Biochemistry, the 2021 AACC Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research, and the 2023 Van Slyke Award from the American Association for Clinical Chemistry (AACC) recognizing his outstanding achievements and excellence in research, service, and contributions to clinical chemistry and laboratory medicine.

Prof. Nirupma Trehanpati

Qualifications: MSc, PhD

Current positions: Professor, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi; Faculty, WHO Collaborating Centre on Chronic Liver Diseases and Viral Hepatitis, New Delhi, India. Contact: trehanpati@ilbs.in, trehanpati@gmail.com, Tel: +91-9540946971, ORCID ID: 0000-0002-6109-0033.

Other Experiences:
• Visiting Scientist in the Department of Pathology, The Center for Systems Immunology, School of Medicine, Case Western Reserve University, from 17th Feb-27th Feb, 2020 under the HIPC collaboration. Indo-US Project
• Visiting Scientist in the Westmead Clinical School, Faculty of Medicine, University of Sydney from 1st-20th Sep, 2018
• Visiting Scientist in the laboratory of Innate Immunology, NIAID National Institute of Health, Maryland, USA, in 2014
• Visiting Scientist in the laboratory of Innate Immunology, NIAID National Institute of Health, Maryland, USA, in 2010
• Visiting Scientist in the laboratory of Innate Immunology, NIAID National Institute of Health, Maryland, USA, in 2007
• Visiting researcher to University of Birmingham, Liver Research Group, Division of Medical Sciences, Birmingham, 2006
• Visiting scholar to German Research Center for Biotechnology, Braunschweig, Germany in 2005
• Vice-Chairperson in IC-SCR of DATT Mediproducts Pvt. Ltd.

Honors:
• Guest Lectures at Westmead Clinical School, Faculty of Medicine, University of Sydney during the visiting scientist tenure in Sep, 2018
• Guest Lecture at Center for Research on Inflammation (CRI), INSERM University of Paris on 25th April, 2017
• Plenary Paper Award in AASLD 2013, USA
• Best Paper in Viral Hepatitis Conference, Frankfurt 2013
• Presidential Paper Award at Prestigious Hepatology meet at AASLD 2012
• Bill and Melinda Gates Travel Grant for the Ninth Annual Conference of Vaccine Research, Baltimore, USA, 11th May 2006
• Travel Grant from HIV and Liver Diseases, Wyoming, 11th-14th Sep, 2006
• Best Paper in Indian Society of Gastroenterology, Nov 2005
• DST Young Scientist, 2003
• CSIR POOL Officer, 1998-2001
• CSIR Research Associate, 1994-1997
• CSIR Senior Research Fellow in Ph.D
• Lady Tata Memorial Fellowship in Ph.D

Contribution to Science:
Total Publications: 114; Career citations >2200; Career citations since 2019 = 750; Total h-index 24; i10 index 37; 5 with >100 cites, 6 with >50 cites. One published article was the subject of editorial commentary (Liver Cancer) and one published article appeared on the cover page of the journal (Hepatology).

Prof. Egon Amann

Egon Amann is an independent consultant in Life Sciences, Quality Systems, and Clinical Chemistry. He is Professor Emeritus at the University of Applied Sciences in Hamm-Lippstadt, Germany, where he was Head (Dean) of the Master Studies “Biomedical Management and Marketing”. He still lectures in Quality Assurance and Product Legislation, Quality and Risk Management, Clinical Chemistry, and Synthetic and Molecular Biology.

Prior to his current posts, he was an Honorary Professor in Molecular Biology and Genetics at Philipps University in Marburg, Germany.

Egon has long-time experience in the pharmaceutical and diagnostic industries. He was an executive employee with Behringwerke AG, Dade Behring Diagnostics, Siemens Healthcare Diagnostics, and Hoechst AG in Germany. He spent many years in human vaccine and human plasma protein R&D and in diagnostic assays development in Germany, Japan, and the US.

Egon has 18 patents granted and more than 80 peer-reviewed publications, along with several book chapters in the areas listed above.

Egon is currently Co-Chair of the IFCC TF-GLQ (Task Force on Global Lab Quality). Previous IFCC assignments included Chair of the Working Group DQCML (Developing Quality Competence in Medical Laboratories) and Chair of C-AQ (Committee on Analytical Quality).

Prof. Ashwin Laxmikant Kotnis

Ashwin Kotnis is Professor of Biochemistry at All India Institute of Medical Sciences Bhopal. He leads an interdisciplinary research team working on predisposition to vitiligo, head-neck cancer, and IgA deficiency diseases funded by DST-SERB, DHR, ICMR, and MPCST in collaboration with several institutes across India.

His interest in onco-immunology and autoimmune disease arose during his PhD at ACTREC, followed by a postdoctoral fellowship at Karolinska Institute, Sweden, and University of Oxford, England, where he published on the role of DNA repair defects in lymphomas and class switch recombination.

As a FAIMER Fellow, he is an avid teacher designing interactive courses on the clinical relevance of lipid metabolism and immunology for MBBS and MD students, along with research mentoring for medical undergraduates. His team’s research has been published, and he has been awarded the EMBO Short Term Fellowship, Lancet Travel Grant, Tata Grant, and other fellowships.

He serves on Ethics and Clinical Trial committees in and around Bhopal and is on the Editorial Review Board of several journals. He guides Postdocs, MD students, Research Fellows, and PhD candidates who have won awards from ICMR, MPCST, and ACBICON for their research papers.

Dr. Swarup A.V. Shah

Dr. Swarup Shah is an experienced molecular scientist with over a decade of experience in molecular diagnostics and omics research, including genomics and transcriptomics. His primary interests focus on translational research, particularly in the field of coronary artery disease, pharmacogenetics, precision medicine, and rare genetic disorders such as familial hypercholesterolemia.

Currently, Dr. Shah serves as a senior molecular scientist at P. D. Hinduja Hospital & Medical Research Centre in Mumbai and is an executive committee member of Emerging Technologies Division of the International Federation of Clinical Chemistry and Laboratory Medicine (EC-ETD, IFCC).

Throughout his research career, Dr. Shah has actively contributed to academia and research and has authored over 30 peer-reviewed publications, with more than 700 citations. He played a key role in conducting the first comprehensive reference interval study for over 50 biochemical analytes in healthy Indian volunteers, as part of the IFCC's global reference interval study led by the IFCC C-RIDL committee.

Dr. Shah’s research has been recognized through numerous national and international awards including the Young Scientist Award from APFCB, Best Poster Award from the European Society of Pharmacogenomics and Personalised therapy (ESPT) along with multiple international travel awards from organizations such as IFCC, APFCB, AMP etc. Dr. Shah is also a recognized PhD mentor at the University of Mumbai and serves as principal investigator for several ICMR-funded research projects.

Additionally, he is a member of various scientific organizations such as ADLM, CPIC, APSAVD, ACBI etc. Dr. Shah serves on the editorial boards of notable journals such as Clinical Chemistry and Laboratory Medicine (CCLM) and is also a reviewer for several prominent international journals.

Prof.Rajvir Dahiya

Dahiya finished his PhD in 1983 in the field of Experimental Medicine from Post Graduate Institute of Medical Education and Research Chandigarh, India. After completing his PhD, Dahiya joined the University of Chicago Pritzker School of Medicine and did his postdoctoral fellowship in medical oncology and molecular biology. After completing his fellowship, Dahiya joined UCSF School of Medicine and San Francisco Veterans Affairs Medical Center (VAMC) in 1987. Dahiya received his M.D. from the Kagoshima University Faculty of Medicine, Kagoshima, Japan and D.Sc. from the Osaka University Graduate School of Medicine, Osaka, Japan. He became director of Oncology Urology Oncology Research Center at the UCSF/VAMC in 1991. After 34 years of service at the UCSF, he retired as a Professor Emeritus and Director of Urology Research Center. Also retired as a Senior Research Career Scientist from the Department of Veterans Affairs, Washington DC. Dahiya has published more than 600 original research manuscripts. Dahiya’s world ranking in medicine is 4759 and USA ranking is 2644 with more than 36,500 research citations and D-index of 107 in 2024. He has written books and holds multiple patents in oncology. Based on the NIH and VA data base NIH Reporter and Grantome, Dahiya's research programs were supported (99 times awarded) by the NIH and VA. Dahiya was a scientific adviser to the President of India Dr. A.P.J. Abul Kalam (11th President of India from 2002-2007). Dahiya is an Associate Editor of Clinical Cancer Research (2012-present) an Academic Editor of “PLoS ONE, (2012-present), a senior academic editor of American Journal of Cancer Research. (2015-present) and was an Associate Editor of Cancer Research (2000-2012).

In 2021, Dahiya started a company named 'Geneverify Inc' in the USA, focusing on developing gene-based testing for screening, early diagnosis, prognosis, treatment follow-up, and gene therapy for various cancers. He has received five USA patents for this technology and is working with the Government of India to transfer this technology, which could save the lives of millions of cancer patients.

: Dr.Suresh Kumar Verma

Dr. Verma is an Associate Professor in the Department of Medicine at the University of Alabama at Birmingham. Trained in biochemistry, Dr. Verma earned his PhD from the Department of Biochemistry at PGIMER Chandigarh in 2007. He completed postdoctoral training first at the Cardiovascular Research Institute, Texas A&M, focusing on Renin Angiotensin signaling in cardiovascular disease, and later at Northwestern University's Department of Medicine, investigating inflammation's role in heart failure progression. Recognized for his exceptional performance, Dr. Verma was promoted to Assistant Professor at Northwestern University in 2012.

In 2014, Dr. Verma received a prestigious Scientist Development grant from the American Heart Association to study the role of bone marrow progenitor cells in cardiac fibrosis and heart failure progression in hypertrophic HF models. He subsequently joined Temple University, Philadelphia, as an Assistant Professor. Currently, Dr. Verma holds dual appointments as an Associate Professor of Medicine and Biomedical Engineering at the University of Alabama at Birmingham, Birmingham Alabama, where he also serves as Director of the Fellows Research Seminar Series.

Dr. Verma's research focuses on identifying novel signaling mediators in cardiovascular disease regulation. His laboratory is supported by major federal agencies and private foundations, resulting in over 55 publications in high-impact journals such as Circulation, Circulation Research, Cardiovascular Research, and Nature Communications. He has mentored more than 25 students and fellows and has received numerous awards, including the AHA Outstanding Early Career Investigator Award.

Prof. Kalyan Goswami

Dr. KALYAN GOSWAMI, MBBS, MD (Biochemistry)

More than 24 years of professional experience after MD degree from Institute of Medical Sciences, Banaras Hindu University. Presently, Professor & Head, Department of Biochemistry and Dean, Academics, AIIMS Kalyani.

Research interest: Oxidative, glycative & metabolic stress, apoptosis & immunomodulation for drug development, bio-statistical application in quality control; non-conventional & integrated teaching in medical education.

Completed 4 projects and presently involved in 4 other ongoing projects from ICMR, DHR and DST.

Fellow of FAIMER (Federation for Advancement of International Medical Education and Research); Trained from National teachers’ training Centre, JIPMER, Puducherry.

Trained in Applied aspects of Biostatistics from Human Genetics Unit of Indian Statistical Institute, Kolkata.

Trained in ‘Qualitative Methods in Health Research’ at Sushila Nayar School of Public Health, MGIMS. Participated in ‘Ethics in clinical research’ from KEM, Mumbai.

Served as Secretary, Institutional Ethics Committee, MGIMS, Sevagram.

Trained in ‘Quality Control and Method Validation’ by CDC, Atlanta, USA and ‘Labs for Life’ programme of Ministry of Health & Family Welfare, Govt. of India in New Delhi. Resource person for training of Lab personnel in statistical quality control at various national level workshops.

Editorial-board member: Indian Journal of Clinical Biochemistry.

Reviewer-STRIDE scheme projects under UGC and SPARC scheme projects of IIT.

Member of ICMR National Taskforce for establishment of Reference interval in Indian Population.

Published 105 Articles (85 International) with more than 2200 citations; h index-25.

Contributory editor: Lippincott’s Illustrated review of Biochemistry, South Asian Edition, 2020. Authored chapters in 4 books.

One United States Patent in credit: Novel diagnostic marker, a diagnostic kit, and a method for diagnosis of rheumatoid arthritis. Two other patents filed.

Dr. Emma English

Dr. Emma English completed her PhD in Biochemistry and undertook Clinical Scientist training at Addenbrooke’s Hospital in Cambridge, holding HCPC registration. After several years at Addenbrooke’s, she transitioned to higher education to support the learning of those passionate about clinical laboratory medicine. Emma then moved to the University of Nottingham, School of Graduate Entry Medicine, to develop new courses for scientists and health professionals.

Emma has extensive experience teaching and learning across a wide range of health programs at both undergraduate and postgraduate levels. While at the School of Health Sciences at UEA, she served as Director of Postgraduate Research and as the academic lead for course development from concept through to accreditation. She is now the Head of the Medicine, Health and Life Sciences portfolio at the University of Cambridge, Institute of Continuing Education.

In her broader educational roles, Emma chairs an IFCC international education committee on diabetes biomarkers. This committee collaborates with global stakeholders to develop and implement effective diabetes testing methods. Her work particularly focuses on enhancing diagnostic provision in low-resource settings. Emma has numerous publications in this area and is a lead author on global guidelines for quality testing of diabetes, including several key World Health Organization (WHO) publications. She also serves as a consultant to WHO and other health-related NGOs.

Prof. Rajat Sandhir

Dr. Rajat Sandhir received his M.Sc and Ph.D. degrees in Biochemistry from the Postgraduate Institute of Medical Education and Research, Chandigarh. He has been at the Department of Biochemistry, Panjab University for over 20 years and brings 30 years of teaching and research experience. His research focuses on understanding the biochemical and molecular mechanisms involved in neurodegenerative conditions such as metabolic encephalopathies, dementias, and brain injury. He investigates the role of oxidative stress, mitochondrial dysfunctions, and alterations in the permeability of the Blood-Brain-Barrier, and seeks to identify neuroprotective strategies to ameliorate these conditions.

Dr. Sandhir has published over 200 papers and has mentored more than thirty Ph.D. students. He has an h-index of 52 and an i10-index of 154. His notable awards include the KT Shetty Memorial Oration (2021) from the Indian Academy of Neurosciences, the Mrs. Abida Mahdi Award–2022 from the Indian Academy of Biomedical Sciences, and the INSA Best Teacher Award 2022. He has also been listed among the World’s Top 2% Scientists for 2020 and 2023 by Stanford researchers. He is a Fellow of the Indian Academy of Neurosciences and the Indian Association of Biomedical Scientists. Dr. Sandhir is also a Principal Investigator of the Northern Region S & T Cluster (PI-RAHI) sanctioned by the Office of the Principal Scientific Adviser, Government of India. He serves on the editorial boards of several international journals.

Prof. Medha Rajappa

Dr. Medha Rajappa is a Professor of Biochemistry and Coordinator of the Bioinformatics Facility at Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) in Puducherry, an Institution of National Importance under the Ministry of Health and Family Welfare. Dr. Rajappa plays a pivotal role in educating and mentoring medical students, residents, and fellows. She is also the Principal Investigator for several projects in cutaneous immunology and chronic kidney disease biology, funded by ICMR, SERB, DBT, and others. Her research focuses on improving diagnostic accuracy and developing novel biomarkers to enhance outcomes in inflammatory skin disorders and chronic kidney disease.

Dr. Rajappa has published 120 research articles with a total citation count of 3282, an h-index of 33, and an i10-index of 75. She has received numerous awards at both national and international levels, including the JIPMER Faculty Research Award-Basic Sciences 2023-2024; Supervisor for ICMR CNMC STS Excellence Award 2019; Mrs. & Dr. G. P. Talwar Oration Award-2023 at ACBICON-2023; Dr. G. P. Talwar Mid-Career Scientist Award in 2017; Outstanding Clinical Researcher of the Decade Award at the 4th National Evidence-Based Medicine and Clinical Research Conference; Kusum Sharma Award from the Indian Academy of Biomedical Sciences in 2015; and several travel grants and research awards.

She served as Associate Dean (Research) from 2019-2023, significantly contributing to research capacity building at JIPMER. Prof. Rajappa is dedicated to enhancing patient outcomes through her expertise, commitment to high-quality patient care, and contributions to research and academia.

Prof. Sergio Bernardini

Prof. Sergio Bernardini, MD, PhD

• Post Graduated in Pediatrics and in Clinical Biochemistry and Chemistry
• Master in Health Economy and Management
• Full Professor in Clinical Biochemistry and Clinical Molecular Biology at the University of Tor Vergata, Department of Experimental Medicine, Via Montpellier 1, cap 00133; Rome, Italy
• Publications H Index: 52
• Head Physician of Laboratory Medicine Department at the Tor Vergata University Hospital, Viale Oxford 8, cap 00133, Rome, Italy
• Past President of the Italian Society Clinical Biochemistry and Laboratory Medicine (SIBioC) 2018-2019
• Past Secretary of the International Federation Clinical Chemistry and Laboratory Medicine (IFCC) 2012-2017
• Chair of the IFCC Emerging Technologies Division 2018-2023
• IFCC Secretary 2024-2026

Contacts:
Mobile: +39 3804399292
Office: +39 0620902262
Mail: sbernardini.med@gmail.com

: Dr. Shyamali Pal

"Dr. Shyamali Pal is PhD Biochemistry with experience in the field of laboratory medicine for more than 40 yrs. She is currently Consultant Biochemist & Technical Director in Allergimmuno Diagnostics Private Limited. She is Lead assessor in NABL and Assessor for medical laboratory, Proficiency testing and Calibration Reference Material in IAS, USA. She is corresponding member of Task Force, Global Lab Quality, IFCC, member of Technical Inspection Committee of IAS, USA. Dr Shyamali Pal is Fellow of ACBI, Pattabiraman Oration awardee, PT provider of an accredited Proficiency testing scheme, PRE-EQC. "

Prof.Tahir

Prof Tahir Pillay is Professor and Head of the Department of Chemical Pathology and overall Pathology Head, University of Pretoria & National Health Laboratory Service(NHLS), Honorary Professor of Chemical Pathology, University of Cape Town (UCT) in South Africa. He is also Chair of the Communications and Publication Division(CPD) of the International Federation of Clinical Chemistry & Laboratory Medicine (IFCC), the first person from Africa to lead a division of the IFCC in its 75 year history. He is also currently the highest research rated chemical pathologist in South Africa by the National Research Foundation, South Africa. He is a board member of the World Association of Pathology & Laboratory Medicine (WASPALM) and the Medical Research Council(MRC), South Africa. He is also one of only two pathologists in South Africa who is an elected member of the Academy of Science of South Africa.

He is a former Editor-in-Chief of the Journal of Clinical Pathology. Prof Pillay has an MBChB cum laude ( University of Natal ), PhD in biochemistry ( University of Cambridge). He completed his postgraduate specialist training at Imperial College and postdoctoral training in molecular and cellular endocrinology at University of California San Diego. He is a Fellow of the Royal College of Pathologists, London and the College of Pathologists, South Africa. Prof Pillay’s research publications spans molecular cell biology of insulin signalling and insulin resistance, molecular modelling of ligand-receptor complexes and application of new diagnostic methods for lipid disorders. He is also a chapter author in the latest editions of the Tietz Textbooks of Laboratory Medicine and the Tietz Fundamentals of Laboratory Medicine.

In 2023 and 2024, he was listed in the Pathologist magazine Power List as one of the Top 100 most influential people in pathology – specifically, as one of the Top 20 Champions for Change.

Prof. Purvi Purohit

Prof (Dr) Purvi Purohit (PhD Biochemistry) is Professor in the Dept of Biochemistry, All India Institute of Medical Sciences Jodhpur. Her research interests are clinical and molecular basis of Diabetes Mellitus, Metabolic Syndrome, Breast Cancer, thanatochemistry, and molecular psychiatry.

She is the recipient of Global Investigator Award 2021 (KSCC), ICMR travel fellowship (2018), IFCC -Roche fellowship (2017), and NIMS-ACBICON Award 2014. She is the corresponding member of IFCC-C-CMBC for ACBI, Academic editor of PLOSone, and Review editor Frontiers Oncology-Breast Cancer.

She is an expert member of the ICMR-NCD Project review committee (Discovery division), Union Public Service Commission subject expert, and Fellow of the Royal Society of Biology.

She has published more than 69 original research articles in various peer-reviewed international and national journals. She is the author of two books and five book chapters on molecular medicine and precision medicine in cancer.

She has received funding from ICMR, DHR, DBT, and RSSDI. Currently, she is working on tumour micro-environment immune modulation in Breast cancer, immune modulation in diabetes mellitus and its complications, biomarker discovery in MDD, toxicologic effects of Bisphenols in NCDs, and determination of time since death in human cadavers using autophagy proteins.

Prof. Jatinder K. Lamba

Dr. Lamba is the Associate Dean for Research and Graduate Education, Professor, and Frank A. Duckworth Eminent Scholar Chair at the University of Florida. Her research focuses on Acute Myeloid Leukemia (AML), a devastating disease with dismal outcomes, and utilizes systems biology-based multi-omic approaches to establish diagnostic and prognostic factors of clinical utility in AML.

Dr. Lamba employs bioinformatics and machine learning approaches across multiple omics factors (genomics, epigenomics, transcriptomics, proteomics, and metabolomics) to define markers of prognostic and therapeutic relevance in AML. This research aims to develop prognostic scores that identify patients at higher risk of disease resistance/relapse, establish pathways of drug-resistance, and identify agents with the potential to overcome resistance to standard chemotherapy.

Dr. Lamba has secured over $11 million in research funding from the NCI and other foundations such as the Leukemia Lymphoma Society, American Cancer Society, St. Baldrick’s Foundation, and the Live Like Bella Foundation. Notable discoveries from her group include CD33 polymorphisms of significant clinical relevance to gemtuzumab response (JCO, 2017) and a pharmacogenetics-based polygenic score that provides prognostic significance and suggests alternative treatment strategies (JCO, 2022).

To pursue this translational research, Dr. Lamba has built a strong team of clinical investigators across multiple institutes, allowing trainees to gain skills at multiple levels. She is actively involved in teaching and mentoring trainees, including postdoctoral and Hem/Onc fellows and graduate students. Several of her trainees have been successfully recruited into academia, industry, and the NCI.

Prof.Tony Cecil Badrick

Tony Badrick AM, BAppSc, BSc, BA, M Lit St (Math), MBA, PhD (QUT), PhD (UQ), FAIMS, FAACB, FACB, FAIM, Member Aust Maths Soc, FRCPA (Hon), FFSc(RCPA), GAICD.

He is the CEO of the Royal College of Pathologists of Australasia Quality Assurance Programs; Adjunct Professor at the School of Pharmacy and Pharmacology, Griffith University, Honorary Associate Professor at the National Centre for Epidemiology and Public Health ANU College of Health and Medicine and ANU College of Science, Honorary Associate Professor, Faculty of Medicine, Bond University, Gold Coast, Visiting Fellow, Australian Institute for Health Innovation, Macquarie University. He is president of the Asian Pacific Federation of Clinical Biochemistry and Laboratory Medicine, a member of the Executive Board of the International Federation of Clinical Chemistry, and the Chief Examiner of the Faculty of Science of the Royal College of Pathologists of Australasia.